MHRA issues MS treatment risk update

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

MHRA issues MS treatment risk update

Postby MSUK » Fri Mar 04, 2011 7:22 am

Image


Risk of progressive multifocal leukoencephalopathy (PML) is increased in patients receiving natalizumab (Tysabri) who have had previous immunosuppressant treatment.

The UK medicines regulator MHRA has issued a new warning over the MS treatment natalizumab (Tysabri).

There is already a risk of progressive multifocal leukoencephalopathy (PML) with the treatment, which was known when it was given a licence. PML is a potentially deadly - but rare - progressive, and demyelinating brain disease.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1905
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2090
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Re: MHRA issues MS treatment risk update

Postby HarryZ » Fri Mar 04, 2011 10:01 am

squiffy2 wrote:Image


Risk of progressive multifocal leukoencephalopathy (PML) is increased in patients receiving natalizumab (Tysabri) who have had previous immunosuppressant treatment.


I"m surprised that they are just now starting to advise Tysabri patients of this increased risk. It is a well known fact that previous users of immunosuppressant drugs are in a higher risk category for PML. Makes you wonder.

Harry
User avatar
HarryZ
Family Elder
 
Posts: 2445
Joined: Tue May 25, 2004 3:00 pm
Location: London, ON, Canada


Return to Tysabri (Antegren or Natalizumab)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users